The next-generation version of Pfizer'sPFE $6 billion pneumococcal vaccine franchise topped its predecessor in a midstage study, the S&P 500 drug giant said Wednesday. Pfizer compared four doses of ...
Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter. Pfizer Inc. (PFE) is running a Phase 3 trial titled “A Phase 3, Randomized Double-Blind Trial to ...
The aim of the study is to understand if the combination of the vaccines is safe, and the immune response after adding the ...
India's patent office has granted Pfizer a patent on its pneumococcal conjugate vaccine (PCV), known as Prevnar 13, after Doctors Without Borders (MSF) challenged the patent’s claims. The decision ...
Please provide your email address to receive an email when new articles are posted on . Researchers compared the 21-valent vaccine to a combination of a 15-valent and 23-valent vaccines. Fewer adverse ...
HONG KONG, Jun 20, 2025 - (JCN Newswire) - - Pneumonia is a form of acute respiratory infection, that is common in all age groups and can cause mild to life-threatening illness. It is also the single ...
Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter GlaxoSmithKline (GSK) has completed a Phase 1 trial titled “A Phase 1, Observer-Blind, ...
Sequential administration of the 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent polysaccharide vaccine (PPSV23) led to nonsignificant increases in memory B cells by week 28 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results